Open Access Repository

Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome

Download Statistics

Downloads

Downloads per month over past year

Ding, C 2006 , 'Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome' , Current Opinion in Investigational Drugs, vol. 7, no. 11 , pp. 1020-1025 .

Preview

PDF
vx-702.pdf | Download (221kB)
Available under University of Tasmania Standard License.
| Preview

Official URL: http://www.biomedcentral.com/1472-4472/7?issue=11

Abstract

Vertex Pharmaceuticals Inc, in collaboration with Kissei
Pharmaceutical Co Ltd, is developing VX-702, one of a series of second-generation, orally active p38 MAP kinase inhibitors, for the potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases. In June 2005, a phase II clinical trial of VX-702 was initiated in rheumatoid arthritis. In July 2006, Vertex was planning to file an IND in the second half of 2006.

Item Type:	Article
Authors/Creators:	Ding, C
Journal or Publication Title:	Current Opinion in Investigational Drugs
ISSN:	1472-4472
Additional Information:	restricted - published by Thompson
Item Statistics:	View statistics for this item

Actions (login required)

Item Control Page

TOP